INTERIM REPORT JANUARY–JUNE 2026

Continued growth

Reporting period April – June 2026

- The Group reported net revenue of 5,963 (2,700) KSEK for the second quarter.
- Operating loss for the second quarter amounted to -3,095 (-538) KSEK.
- Earnings per share, both basic and diluted, were-0.36 (-0.16) SEK for the period.
- Cash flow for the second quarter amounted to -3,456 (-1,224) KSEK, and cash and cash equivalents totaled 16,828 (5,989) KSEK at the end of the quarter.

Reporting Period January – June 2026

- For the first half-year, the Group's net sales amounted to 10,943 (5,927) KSEK.
- Operating profit for the first half-year amounted to -5,861 (-1,972) KSEK.
- Earnings per share, basic and diluted, were -0.69 (-0.44) SEK for the period.
- Cash flow for the first half-year amounted to 12,495 (-3,411) KSEK, and cash and cash equivalents totaled 16,826 (5,989) KSEK at the end of the quarter.

Comparative figures in parentheses refer to the corresponding period of the previous year, unless otherwise stated.

Events During the Reporting period April–June 2026

- Perpetua Medical AB expanded its management team by appointing Thomas Pousette, an experienced corporate lawyer with many years in the medical technology sector.
- The Annual General Meeting of Perpetua Medical AB was held on 29 May 2026. The meeting resolved all proposed agenda items in accordance with the Board's recommendations, as presented in the notice convening the meeting.
- At the Annual General Meeting, a new Board member, Olof Stranding, was elected. Wilhelm Risberg stepped down from the Board.

Comments from the CEO

Dear Shareholders,

Revenue growth was strong during the quarter, supported by continued cost discipline. To bring the Group to positive cash flow, we need to complete additional acquisitions. During the second quarter, we continued to engage in parallel discussions and negotiations with the owners of several potential acquisition targets. A couple of these processes remain ongoing. At the time of writing, my assessment is that we have a handful of discussions or negotiations that could potentially lead to transactions in the relatively near term. The words "at the time of writing" are important, as M&A is inherently unpredictable. Ultimately, both parties need to agree on the terms of a transaction.

In parallel with our acquisition activities, we are gradually developing our subsidiaries, ES-Medical and Spirotronic.

ES-Medical's transformation into a global medical technology product company continues to progress. The team is doing an outstanding job of maintaining revenues while we increase our investments in the company. During the second half of the year, we look forward to communicating more explicitly about the approaching launch of our first proprietary product.

During 2026, Spirotronic has initiated sales and marketing activities targeting ventilator manufacturers. The objective is for next-generation ventilators and anesthesia machines to be launched with Spirotronic components integrated into the systems. The company is currently in discussions with several manufacturers with significant annual production volumes.

We continue to move forward with persistence and respect for the complexities inherent in the acquisition process. There are no shortcuts. At the same time, I am more convinced than ever that our systematic approach will deliver results and lead to further high-quality acquisitions.

Finally, I would like to extend my sincere thanks to our Board of Directors, management team and the employees of our subsidiaries for the outstanding work they carry out every day across the Perpetua Group. I would also like to thank our shareholders for your continued support during this important phase of building the Group.

Uppsala August,

Anders Hedlund

Anders Hedlund, CEO of Perpetua Medical AB (publ)

Perpetua Medical in brief

Perpetua Medical is a serial acquirer of profitable businesses within the healthcare sector. The company applies a decentralized ownership model, where the decision-making and operations occur in independent subsidiaries. The time horizon is long-term without any explicit exit strategy and is reflected in the company name.

The company is listed on Nasdaq First North Stockholm (PERP B).

Group performance in the second quarter

Revenue and expenses - Second Quarter

The Group's net sales for the second quarter amounted to 5,963 (2,700) KSEK, corresponding to an increase of approximately 121 percent compared with the second quarter of the previous year. Spirotronic AB was acquired on 1 September last year, and the additional revenue from Spirotronic represents the largest contribution to the increase in the Group's net revenue compared with the same period last year. ES Medical AB's net revenue was 0.6 MSEK higher than in the corresponding period of the previous year.

Other operating income for the period amounted to 1,624 (254) KSEK, primarily attributable to capitalized development costs in both subsidiaries during the quarter. The change compared to the previous year is due to the addition of Spriotronic to the Group and the fact that the development project in ES Medical was in its start-up phase during the previous year.

The Group's operating expenses for the second quarter amounted to -10,681 (-3,492) KSEK. Compared with the previous year, operating expenses include costs attributable to Spirotronic. Personnel expenses for the second quarter of 2026 amounted to -3,896 (-956) KSEK. The increase in personnel expenses compared with the previous year is primarily a result of the acquisition of Spirotronic in the third quarter of 2025, as well as the addition of one employee in ES Medical AB. The number of employees at the end of the period was 12 (3).

Other external expenses amounted to -2,104 (-1,245) KSEK in the second quarter, also reflecting the acquisition of Spirotronic and increased costs in ES Medical related to the ongoing development project. Depreciation primarily relates to amortization of intangible assets, such as goodwill, attributable to the two subsidiaries.

Operating profit – Second Quarter

The Group's operating profit for the second quarter amounted to -3,095 (-538) KSEK. The difference compared with the previous year is mainly due to the inclusion of Spirotronic in the Group, as well as a lower contribution from ES Medical compared with the corresponding period last year. The single largest change relates to additional amortization of intangible assets arising from the acquisition of Spirotronic AB, amounting to 0.8 MSEK.

Cash Flow and Financial Position

Investments – Second Quarter

During the second quarter of 2026, both subsidiaries invested in the development of new proprietary products, totaling -1,546 (-239) KSEK. These investments form part of the strategic shift undertaken by both subsidiaries to increase sales of own products.

Liquidity and Cash Flow – Second Quarter

As of 30 June 2026, the Group's cash and cash equivalents amounted to 16,828 (5,989) KSEK, of which the Parent Company's cash and cash equivalents amounted to 14,077 (1,924) KSEK. Cash flow from operating activities in the second quarter amounted to -1,866 (-985) KSEK, and total cash flow for the period was -3,456 (-1,224) KSEK. Cash flow from investing activities was affected by investments in the development of new products in the subsidiaries.

No further repayments were made during the second quarter on the receivable from Pharmacolog Inc relating to the sale of WasteLog. According to the agreement, the remaining portion of the purchase consideration is to be paid over a period of 24 months from the signing of the agreement with Pharmacolog Inc in early July 2025.

Financial Position

The Group's equity as of the balance sheet date amounted to 25,467 (8,912) KSEK, of which 16,075 (5,735) KSEK is attributable to the Parent Company's shareholders. The Parent Company's equity amounted to 28,377 (4,932) KSEK at the balance sheet date. The Group's equity ratio amounted to 44 (55) percent.

Accounting Policies

This interim report has been prepared in accordance with the Swedish Annual Accounts Act and the general guidelines of the Swedish Accounting Standards Board, BFNAR 2012:1 Annual Report and Consolidated Financial Statements (K3). The accounting policies applied are consistent with those presented in the 2025 Annual Report, published on 17 April 2026, and remain unchanged from the previous reporting period.

Group Structure

The Parent Company, Perpetua Medical AB (publ), corporate registration number 556723-6418, domiciled in Uppsala, prepares consolidated financial statements including its partly owned subsidiaries ES-Medical AB, corporate registration number 559120-1156, domiciled in Uppsala, and Spirotronic AB, corporate registration number 556818-0268, domiciled in Stockholm.

Shares and Shareholders

Current information regarding the shares and shareholders of Perpetua Medical AB (publ) is available on the Company's website: https://perpetuamedical.se/

Risks and Uncertainties

Perpetua Medical's business strategy includes the acquisition of smaller but profitable companies within the healthcare sector. This type of activity is associated with significant uncertainty and risk. The principal risks are described in the 2025 Annual Report, published on 17 April 2026.

Related party transactions

The Company's principal shareholder, Nolsterby Invest AB, is offering the Company a loan facility of up to SEK 25 million. The extraordinary general meeting held on 30 August 2024 approved that the Company may incur loans under the loan facility offered by Nolsterby Invest AB in order to enable the Company to carry out the initial acquisitions under its new business strategy. At the general meeting on 29 May 2026, it was resolved to extend the period during which the Company is entitled to incur additional loans from the facility offered by Nolsterby Invest AB, with all other terms remaining unchanged.

At the time of the offer, Nolsterby Invest AB held 25.1 percent of the shares in Perpetua Medical. As of the balance sheet date, Nolsterby Invest AB holds 29.1 percent of the shares in Perpetua Medical. Nolsterby Invest AB is therefore considered a related party to the Company, which means that the provisions in Chapter 16a of the Swedish Companies Act regarding certain related-party transactions must be taken into account. The key terms of the agreement are as follows:

- The loan facility amounts to a maximum of SEK 25,000,000.
- The interest rate is variable and corresponds to STIBOR 3M + 4 percentage points, however never lower than 6 percent. Accrued interest is payable in arrears at the end of each financial year or upon repayment of principal.
- The facility may only be used for the acquisition of shares in other companies. Written approval from the Board of Directors of Nolsterby Invest AB regarding the intended acquisition is required for a drawdown to be made, unless the Company undertakes to provide satisfactory security for the intended loan.
- Drawdowns may be made on one or several occasions, subject only to the upper limit of SEK 25,000,000.
- The loan matures on 31 December 2028, at which point it shall be repaid. The loan is amortization-free during the term, although the Company is entitled to make voluntary amortizations at any time. In the event of early repayment, accrued interest at the time of repayment shall also be paid by the Company.

Perpetua Medical AB has utilized part of the loan facility by drawing SEK 4 million on 24 September 2024 and SEK 7.7 million on 29 August 2025 under the terms described above, in order to partly finance completed acquisitions. As of the balance sheet date, SEK 13.3 million remains available under the loan facility. The facility approved by the general meeting now allows drawdowns to be made up to and including 30 September 2027.

Auditor Review

This interim report has not been subject to review by the Company's auditor.

Financial calendar

Interim report July-September 2026	20 November 2026
Year-end report 2026	26 February 2027

Annual General meeting

The Annual General Meeting was held on 29 May 2026. Information relating to the Annual General Meeting was made available on the company's website on 30 April 2026 and was further communicated through the meeting communiqué on 29 May 2026. The audited annual report was published on the company's website on 17 April 2026.

Further information

For further information, please contact:
Anders Hedlund, CEO, phone: 018-71 13 32 or
e-mail: anders.hedlund@perpetuamedical.se

Certified Adviser is Mangold Fondkommission AB , Phone: 08-5030 15 50 or e-mail ca@mangold.se.

The interim report is accessible on the company's Website:
Financial reports | Perpetua Medical AB

Perpetua Medical AB (publ), Knivstagatan 8, 753 23 Uppsala
Org no 556723-6418
Phone: +46 18 71 13 32
E-mail: info@perpetuamedical.se
Website: www.perpetuamedical.se

The board of directors signing

Uppsala 21 August 2026

Erik Hedlund
Chairman of the board

Ragnar Linder
Board member

Henrik Magnusson Hjorth
Board member

Kiarash Farr
Board member

Olof Stranding
Board member

Anders Hedlund
CEO

The report was originally written in Swedish and translated into English. In the event of any discrepancies between the two versions, the Swedish version takes precedence.

PERPETUA MEDICAL

Consolidated income statement

Amount in KSEK	**Apr-Jun 2026**	**Apr-Jun 2025**	**Jan-Jun 2026**	**Jan-Jun 2025**	**Jan-Dec 2025**
Revenue					
Net Sales	5 963	2 700	10 943	5 927	14 560
Other Income	1 624	254	2 884	905	11 947
Total Revenue	**7 586**	**2 954**	**13 827**	**6 832**	**26 508**
Cost of goods Sold	-3 445	-980	-5 794	-2 708	-6 959
Other external expenses	-2 104	-1 245	-4 187	-2 916	-7 531
Personnel costs	-3 896	-959	-7 358	-2 142	-7 360
Depreciations	-1 202	-307	-2 404	-614	-2 501
Other operating expenses	-34	0	-39	-1	-113
Total operation expenses	**-10 681**	**-3 492**	**-19 783**	**-8 381**	**-24 464**
Operating profit	**-3 095**	**-538**	**-5 956**	**-1 548**	**2 044**
Financial income and costs					
Results from investments in group companies	0	0	0	0	-232
Interest income and similar items	21	32	256	32	84
Interest expenses and similar items	-38	-61	-233	-158	-703
Total finance income and costs	**-17**	**-29**	**23**	**-126**	**-851**
Tax	36	-157	72	-298	23
Net profit for the period	**-3 076**	**-724**	**-5 861**	**-1 972**	**1 215**
Profit attributable to:					
Parent Company shareholders	-2 174	-814	-4 240	-2 128	2 452
Non-controlling interests	-902	90	-1 621	157	-1 236
Net profit for the period	**-3 076**	**-724**	**-5 861**	**-1 972**	**1 215**
Basic Earnings per share, SEK	-0,36	-0,16	-0,69	-0,44	0,26
Diluted earnings per share, SEK	-0,36	-0,16	-0,69	-0,44	0,26

Consolidated Balanse Sheet

Amount in KSEK	**2026-06-30**	**2025-06-30**	**2025-12-31**
ASSETS			
Subscribed unpaid share capital	0	0	18 676
Non-current assets			
Intangible assets	23 197	5 551	22 692
Tangible assets	1 010	7	1 161
Financial assets	828	52	811
Total non-current assets	**25 035**	**5 609**	**24 663**
Inventories	1 088	1 004	868
Accounts receivable- trade	5 114	2 454	3 635
Other current receivables	8 024	551	7 804
Work in porgress not yet invoiced	1 333	0	1 533
Prepaid expeses and accrued income	709	507	703
Cash and cash equivalents	16 828	5 989	4 333
Total current assets	**33 096**	**10 505**	**18 876**
Total Assets	**58 131**	**16 114**	**62 215**
EQUITY AND LIABILITIES			
Equity			
Share capital	2 054	1 085	1 085
Subscribed not registered share capital	0	0	915
Other contributed capital	20 013	390	19 546
Retained earnings including profit for the period	-5 991	4 260	-1 784
Total Equity attributable to parent company shareholders	**16 075**	**5 735**	**19 762**
Non -controlling interests	9 392	3 176	11 012
Total Equity	**25 467**	**8 912**	**30 775**
Provisions			
Deferred tax liabilities	1 413	545	1 467
Other provisions	10 080	0	10 080
Total provisions	**11 493**	**545**	**11 547**
Non-Current liabilities			
Other Non-Current liabilities	12 376	4 000	12 465
Total non-Current liabilities	**12 376**	**4 000**	**12 465**
Current Liabilities			
Liabilities to credit institutions	178	0	178
Accounts payable -trade	3 407	836	2 065
Other current liabilities	1 775	842	1 735
Invoiced but not yet earned revenue	307	0	939
Accrued expenses and deferred income	3 128	980	2 512
Tolta Current Liabilities	**8 795**	**2 658**	**7 428**
Total Equity and Liabilities	**58 131**	**16 114**	**62 215**

Consolidated statement of change in Equity

Amount in KSEK	Share Capital	Subscribed not registered share capital	Other contributed capital	Retained earnings including profit for the period	Non - controlling interests	Total Equity
Amount per 2025-01-01	**1 085**	**0**	**1 785**	**4 975**	**3 020**	**10 866**
New share issue in progress		915	19 102			20 017
Transaction costs related to share issue			-1 341			-1 341
Exchange differences on traslation of foreign operation				18		18
Non -controlling intersts					9 229	9 229
Provisions for the non-controlling shareholders' put option				-10 080		-10 080
Effect of changes in the parent's ownership interest				851		851
Net profit for the period				2 452	-1 236	1 215
Amount per 2025-12-31	**1 085**	**915**	**19 546**	**-1 784**	**11 012**	**30 775**

Amount in KSEK	Share Capital	Subscribed not registered share capital	Other contributed capital	Retained earnings including profit for the period	Non - controlling interests	Total Equity
Amount per 2025-01-01	**1 085**	**0**	**1 785**	**4 975**	**3 020**	**10 866**
New share issue						0
Transaction costs related to share issue						0
Exchange differences on traslation of foreign operation			18			18
Re-classification of equity			356	-356		0
Net profit for the period			0	-2 128	157	-1 972
Amount per 2025-06-30	**1 085**	**0**	**2 159**	**2 491**	**3 177**	**8 912**

Amount in KSEK	Share Capital	Subscribed not registered share capital	Other contributed capital	Retained earings including profit for the period	Non - controlling interests	Total Equity
Amount per 2026-01-01	**1 085**	**915**	**19 546**	**-1 784**	**11 012**	**30 775**
New share issue	968	-915	1 114			1 167
Transaction costs related to share issue			-614			-614
Re-classification of equity			-33	33		0
Net profit for the period			0	-4 240	-1 621	-5 861
Amount per 2026-06-30	**2 054**	**0**	**20 013**	**-5 991**	**9 392**	**25 468**

Consolidated cash flow statement

Amount in KSEK	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Cashflow from operating activities					
Operating profit	-3 095	-538	-5 956	-1 548	2 044
Adjustments for non-cash items	1 202	292	2 401	632	-7 111
Net financial items	-17	-29	23	-126	-851
Income taxes paid	0	-157	0	-298	-272
Cash flow from operating activities before change in working capital	**-1 910**	**-432**	**-3 531**	**-1 340**	**-6 191**
Cash flow from change in working capital					
increase(-)/decrease(+) in inventories	-136	-30	-220	-234	-98
Increase(-)/decrease(+) in trade receivables	-1 702	289	-1 479	-465	272
Increase(-)/decrease(+) in other current receivables	-418	-217	-35	-339	-784
Increase(+)/decrease(-) in trade payables	1 544	-584	1 343	-554	87
Increase(+)/decrease(-) in other current liabilities	754	-12	24	-123	1 251
Cash flow from operating activities	**-1 866**	**-985**	**-3 898**	**-3 055**	**-5 463**
Cash flow from investing activities					
Investments in business combinations, net	0	0	0	0	-8 441
Investments in intangible assets, net	-1 546	-239	-2 748	-356	1 265
Investments in property, plant and equipment, net	0	0	0	0	-1 070
Change in financial non-current assets, net	0	0	0	0	-1
Cash flow from investing activities	**-1 546**	**-239**	**-2 748**	**-356**	**-8 247**
Cash flow from financing activities					
Proceeds from new share issue	0	0	19 230	0	0
Proceeds from borrowings	0	0	0	0	8 770
Repayment if borrowings	-45	0	-89	0	-126
Cash flow from financing activities	**-45**	**0**	**19 140**	**0**	**8 643**
Net change in cash and cash equivalents	**-3 456**	**-1 224**	**12 495**	**-3 411**	**-5 067**
Cash and cash equivalents at beginning of the period	20 284	7 213	4 333	9 400	9 400
Cash and cash equivalents at the end of the period	16 828	5 989	16 828	5 989	4 333

Consolidated key preformance indicators

	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Net Sales, KSEK	5 963	2 700	10 943	5 927	14 560
Operating Profit, KSEK	-3 095	-538	-5 956	-1 548	2 044
Total Equity attributable to parent company shareholders	16 075	5 735	16 075	5 735	19 762
Total Equity	25 467	8 912	25 467	8 912	30 775
Equity ratio, %	44%	55%	44%	55%	49%
Total Assets, KSEK	58 131	16 114	58 131	16 114	62 215
Quick Ratio	364%	357%	364%	357%	242%
Weighted average number of shares before dilution	8 556 820	4 521 674	8 533 486	4 521 674	4 657 474
Weighted average number of shares after dilution	8 556 820	4 521 674	8 533 486	4 521 674	4 657 474
Basic Earnings per share, SEK	-0,36	-0,16	-0,69	-0,44	0,26
Diluted earnings per share, SEK	-0,36	-0,16	-0,69	-0,44	0,26
Number of shares, end of the period	8 556 820	4 521 674	8 556 820	4 521 674	4 521 674
Equity per share, SEK	1,88	1,27	1,88	1,27	4,37
Number of employees, end of period	12	3	12	3	11

Parent company income statement

Amount in KSEK	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Revenue					
Net Sales	65	73	99	104	128
Other Income	41	0	41	435	9 894
Total Revenue	**106**	**73**	**141**	**539**	**10 022**
Cost of goods Sold	0	0	0	3	3
Other external expenses	-978	-898	-1 996	-2 306	-4 298
Personnel costs	-263	-167	-528	-602	-1 131
Depreciations	0	-3	0	-7	-7
Other operating expenses	0	0	0	-1	-4
Total operation expenses	**-1 241**	**-1 068**	**-2 524**	**-2 913**	**-5 436**
Operating profit	**-1 136**	**-995**	**-2 384**	**-2 374**	**4 585**
Financial income and costs					
Results from investments in group companies	0	0	0	170	170
Interest income and similar items	64	10	315	-22	11
Interest expenses and similar items	-24	-61	-206	-124	-626
Total finance income and costs	**41**	**-51**	**109**	**25**	**-445**
Net profit for the period	**-1 095**	**-1 046**	**-2 275**	**-2 350**	**4 140**

Parent Company Balance sheet

Amount in KSEK	**2026-06-30**	**2025-06-30**	**2025-12-31**
ASSETS			
Subscribed unpaid share capital	0	0	18 676
Non-current assets			
Tangible assets	0	7	0
Financial assets			
Shares in Group Companies	17 087	6 833	15 587
Receivable from Group Companies	2 000	0	0
Other Non-current Receivables	52	52	52
Total Non-current assets	**19 139**	**6 891**	**15 639**
Current assets			
Accounts receivable- trade	0	0	20
Receivable from Group Companies	468	56	301
Other current receivables	7 174	416	7 445
Prepaid expeses and accrued income	194	200	179
Cash and cash equivalents	14 077	1 924	1 006
Total Current assets	**21 913**	**2 596**	**8 951**
Total Assets	**41 052**	**9 487**	**43 266**
EQUITY AND LIABILITIES			
Equity			
Share Capital	2 054	1 085	1 085
Subscribed not registered share capital	0	0	915
Share Premium Reserve	20 013	1 752	19 513
Retained Earnings	8 585	4 445	4 445
Net Profit for the Period	-2 275	-2 350	4 140
Total Equity	**28 377**	**4 932**	**30 099**
Non-current liabilities			
Other non-current liabilities	11 700	4 000	11 700
Total non-current liabilities	**11 700**	**4 000**	**11 700**
Current Liabilities			
Liabilities to credit institutions	0	0	0
Accounts payable -trade	155	56	531
Other current liabilities	7	7	7
Accrued expenses and deferred income	814	492	930
Total current Liabilities	**976**	**555**	**1 468**
Total Equity and Liabilities	**41 052**	**9 487**	**43 266**

Parent company statement of change in equity

Amount in KSEK	Share Captial	Subscribed not registered share capital	Share Premium Reserve	Retained Earnings	Net Profit for the Period	Total Equity
Amount per 2025-01-01	**1 085**	**0**	**1 752**	**6 809**	**-2 364**	**7 282**
Transfer of prior year's result:						
Balance carried forward				-2 364	2 364	0
New share issue in progress		915	19 102			20 017
Transaction costs related to share issue			-1 341			-1 341
Net Profit for the period					4 140	4 140
Amount per 2025-12-31	**1 085**	**915**	**19 513**	**4 445**	**4 140**	**30 098**

Amount in KSEK	Share Captial	Subscribed not registered share capital	Share Premium Reserve	Retained Earnings	Net Profit for the Period	Total Equity
Amount per 2025-01-01	**1 085**	**0**	**1 752**	**6 809**	**-2 364**	**7 282**
Transfer of prior year's result:						
Balance carried forward				-2 364	2 364	0
Net Profit for the period					-2 350	-2 350
Amount per 2025-06-30	**1 085**	**0**	**1 752**	**4 445**	**-2 350**	**4 932**

Amount in KSEK	Share Captial	Subscribed not registered share capital	Share Premium Reserve	Retained Earnings	Net Profit for the Period	Total Equity
Amount per 2026-01-01	**1 085**	**915**	**19 513**	**4 445**	**4 140**	**30 099**
Transfer of prior year's result:						
Balance carried forward				4 140	-4 140	0
New share issue	968	-915	1 114			1 167
Transaction costs related to share issue			-614			-614
Net Profit for the period					-2 275	-2 275
Amount per 2026-06-30	**2 054**	**0**	**20 013**	**8 585**	**-2 275**	**28 377**

Parent Company cash flow statement

Amount in KSEK	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Cashflow from operating activities					
Operating profit	-1 136	-995	-2 384	-2 374	4 585
Adjustments for non-cash items	0	3	0	7	-9 446
Net financial items	41	-51	109	-146	-615
Cash flow from operating activities before change in working capital	**-1 095**	**-1 042**	**-2 275**	**-2 513**	**-5 476**
Cash flow from change in working capital					
increase(-)/decrease(+) in inventories	0	0	0	0	0
Increase(-)/decrease(+) in trade receivables	12	194	12	145	125
Increase(-)/decrease(+) in other current receivables	-667	-110	-685	-200	-635
Increase(+)/decrease(-) in trade payables	23	-82	-376	-72	404
Increase(+)/decrease(-) in other current liabilities	582	-63	654	11	449
Cash flow from operating activities	**-1 145**	**-1 103**	**-2 671**	**-2 628**	**-5 133**
Cash flow from investing activities					
Investments in intangible assets, net	0	0	0	0	2 941
Change in financial non-current assets, net	-1 500	0	-1 500	170	-8 584
Cash flow from investing activities	**-1 500**	**0**	**-1 500**	**170**	**-5 643**
Cash flow from financing activities					
Proceeds from new share issue	0	0	19 230	0	0
Proceeds from borrowings	0	0	0	0	7 700
Repayment of borrowings	-1 000	0	-2 000	0	-700
Repayment of loans provided	0	0	12	0	400
Cash flow from financing activities	**-1 000**	**0**	**17 241**	**0**	**7 400**
Net change in cash and cash equivalents	**-3 645**	**-1 103**	**13 071**	**-2 458**	**-3 376**
Cash and cash equivalents at beginning of the period	17 722	3 027	1 006	4 382	4 382
Cash and cash equivalents at the end of the period	14 077	1 924	14 077	1 924	1 006

Parent company key performance indicators

	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Net Sales, KSEK	65	73	99	104	128
Operating Profit, KSEK	-1 136	-995	-2 384	-2 374	4 585
adjusted equity	28 377	4 932	28 377	4 932	30 099
Equity ratio, %	69%	52%	69%	52%	70%
Total Assets, KSEK	41 052	9 487	41 052	9 487	43 266
Quick Ratio	2246%	468%	2246%	468%	610%
Weighted average number of shares before dilution	8 556 820	4 521 674	8 533 486	4 521 674	4 657 474
Weighted average number of shares after dilution	8 556 820	4 521 674	8 533 486	4 521 674	4 657 474
Number of shares, end of the period	8 556 820	4 521 674	8 556 820	4 521 674	4 521 674
Equity per share, SEK	3,32	1,09	3,32	1,09	6,66
Number of employees, end of period	1	1	1	1	1
Extended number of Employees, end of period	3	2	3	2	2

Definitions

EARNINGS PER SHARE - Profit after tax, divided by the average number of shares. The metric indicates the net earnings attributable to each share and can be compared with the share price to assess how the company's earnings are valued by the market.

EQUITY PER SHARE – Reported equity attributable to the parent company's shareholders at the end of the period divided by the number of shares outstanding at the end of the period. The metric shows the amount of equity represented by each share and can be compared with the share price to assess how the company's net asset value is valued.

EQUITY/ASSET RATIO – Adjusted equity divided by total assets. The equity ratio indicates the company's capacity to absorb losses.

QUICK RATIO – Total current assets excluding inventories divided by current liabilities. The quick ratio reflects the company's ability to meet its short-term obligations.

TOTAL ASSETS- Total assets at the end of the period according to the balance sheet.

EXTENDED NUMBER OF EMPLOYEES – Employees and consultants with recurring assignments in the company's ongoing operations.